Medicus Pharma reports positive Phase 2 results for microneedle treatment for basal cell carcinoma

Medicus Pharma (NASDAQ:MDCX) said on Thursday that its experimental microneedle-based therapy showed encouraging efficacy in ...

Medicus Pharma stock swings after skin cancer treatment results

Medicus Pharma Ltd. MDCX shares surged to a high of $1.61 before falling during Thursday’s premarket session following the ...

Medicus Pharma CEO discusses Phase 2 skin cancer results - ICYMI

CEO Dr. Raza Bokhari talked with Proactive about the company’s newly reported topline Phase 2 results for its microneedle ...
Healio

Phase 1/2 trial of AiViva Biopharma’s intradermal basal cell carcinoma treatment complete

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. AIV001 (Axitinib) is in development for the nonsurgical ...
Grit Daily

Medicus Pharma’s Pipeline Targets Skin Cancer and Prostate Cancer

When most people think about cancer treatment, they picture chemotherapy, grueling surgeries, harsh drug regimens, and devastating side effects. Medicus ...
Healio

Verrica completes dosing in basal cell carcinoma immunotherapy trial

Please provide your email address to receive an email when new articles are posted on . VP-315 is an oncolytic peptide immunotherapy injected directly into BCC tumors. The phase 2 trial includes 80 ...
The American Journal of Managed Care

Prevalence of Cutaneous Squamous Cell Carcinoma (CSCC) & Basal Cell Carcinoma (BCC)

Panelists discuss the current prevalence and treatment landscape of cutaneous squamous cell carcinoma (cSCC) and basal cell carcinoma (BCC). This is a video synopsis/summary of a Peer Exchange ...